Agomelatine (L (+) -Tartaric acid)

Agomelatine L (+) -Tartaric acid (S-20098 L (+) -Tartaric acid) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine L (+) -Tartaric acid is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].

Product Specifications

CAS Number

[824393-18-2]

Product Name Alternative

S-20098 L (+) -Tartaric acid

UNSPSC

12352005

Target

5-HT Receptor; Endogenous Metabolite; Melatonin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/agomelatine-l__addition__-tartaric-acid.html

Purity

99.82

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(NCCC1=C2C=C(OC)C=CC2=CC=C1)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O

Molecular Formula

C19H23NO8

Molecular Weight

393.39

References & Citations

[1]Audinot V, et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367 (6) :553-61.|[2]Millan MJ, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003 Sep;306 (3) :954-64.|[3]Aguiar CC, et al. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell Mol Neurobiol. 2013 Aug;33 (6) :825-35.